Memorial Hermann has been recognized for its overall performance in serving both individuals and the community. Photo via memorialhermann.org

Houston hospitals have been evaluated by a new ranking to determine the institutions that are doing their best to serve their patients and the community as a whole.

Brookline, Massachusetts-based think tank, The Lown Institute, has revealed its national rankings on its Lown Institute Hospitals Index — which evaluated hospitals based on civic leadership (based on inclusion and access), value of care, and patient outcomes (which evaluates safety and satisfaction).

"At a time when communities are relying on them like never before, hospitals must rethink what it means to be great," says Dr. Vikas Saini, president of the Lown Institute, in a news release. "COVID-19 highlights how hospitals are essential community partners for anyone in need. To be great, however, a hospital cannot only provide care that's high in quality. It must also deliver value and advance equality. Our index is designed to help them do just that."

The Texas Medical Center's Memorial Hermann Hospital ranked as No. 9 on the list that evaluated over 3,000 hospitals in the country. The hospitals are also given a grade on each of the three categories. Memorial Hermann received an A for civic leadership, an A- for value of care, and an A+ for patient outcomes — for an overall A+ grade.

Based on ranking, the Houston area's top 10 hospitals, which all received an overall grade of A- or above, are:

  1. Memorial Hermann Texas Medical Center (No. 9 in the country; No. 3 in the state)
  2. Harris Health System (No. 23 in the country; No. 5 in the state)
  3. Memorial Hermann Northeast Hospital in Humble (No. 165 in the country; No. 15 in the state)
  4. Memorial Hermann Hospital System (No. 297 in the country; No. 17 in the state)
  5. Brazosport Regional Health System in Lake Jackson (No. 304 in the country; No. 18 in the state)
  6. The Woman's Hospital of Texas (No. 373 in the country; No. 25 in the state)
  7. Memorial Hermann Katy Hospital in Katy (No. 374 in the country; No. 26 in the state)
  8. Houston Methodist San Jacinto Hospital in Baytown (No. 627 in the country; No. 43 in the state)
  9. Memorial Hermann Sugar Land Hospital in Sugar Land (No. 648 in the country; No. 44 in the state)
  10. Memorial Hermann Memorial City Medical Center (No. 652 in the country; No. 45 in the state)

The Harris Health System ranked the highest in Houston for civic leadership, and the Memorial Hermann Memorial City Medical Center scored the highest in the region for patient outcomes.

There were three other Texas hospitals among the top 10 in the nation — JPS Health Network in Fort Worth ranked as No. 1, Seton Northwest Hospital in Austin ranked as No. 4, and Parkland Health and Hospital System in Dallas ranked as No. 10.

The point of the study, according to the release, is to hold hospitals accountable for more than just one factor of success.

"There are some very fine hospitals that feel forced to focus on profitable elective procedures to stay in business," says Saini in the release. "This can lead to business decisions that make them look good on outcomes like mortality, but at the expense of equity. The data show that gaps between a hospital's clinical results and its performance in the community are sometimes very wide, which can contribute to disparities in care and put certain communities at risk."

The study factored in data from a variety of sources, including the 100 percent Medicare claims datasets (MEDPAR and outpatient); Internal Revenue Service pulled from Community Benefit Insight database; Healthcare Cost Report Information System administered by the Centers for Medicare and Medicaid Services; Securities and Exchange Commission filings; public records; Bureau of Labor Statistics; and other databases, according to the release.

"No other hospital ranking provides a 360-degree view of hospital performance," says Shannon Brownlee, senior vice president at the Lown Institute, in the release. "Many of the best-known hospitals score highly on patient outcomes but poorly on civic leadership and value of care. Our data show that it's possible to do well in all three categories, because some hospitals are doing it. That means all the people in their communities are being served effectively and fairly."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

NASA unveils Artemis III astronauts at Johnson Space Center in Houston

To the moon

NASA on Tuesday, June 9, revealed the crew for its Artemis III mission, the next step in the space agency's plan to eventually land astronauts on the moon.

The announcement came two months after Artemis II's record-breaking trip around the moon that surpassed the distance record of Apollo 13.

NASA's Randy Bresnik, Frank Rubio, Andre Douglas and the European Space Agency's Luca Parmitano won't fly to the moon or land on the surface. Instead, they’ll orbit Earth while practicing docking their Orion capsule with two lunar landers.

“To the Artemis III crew, we wish you Godspeed on the journey ahead,” said NASA administrator Jared Isaacman.

Elon Musk’s SpaceX and Jeff Bezos’ Blue Origin are racing to deliver the lunar landers. The two-week demo is targeted for 2027. Blue Origin suffered a recent setback when its massive rocket exploded during an engine-firing test on the launch pad in Florida, shaking nearby homes and illuminating the sky with an orange fireball.

NASA's Jeremy Parsons said the setback is a learning opportunity and that the space agency is confident Blue Origin's rocket will be ready in time.

NASA's Artemis program aims to return astronauts to the moon's surface for the first time since the 1970s. A recent revamp of the program announced by Isaacman aims to fast-track it similarly to the Apollo era, adding the upcoming spaceflight around Earth before eyeing a lunar landing in 2028.

“We are certainly humbled as a crew to be able to be your crew that executes this Artemis III mission in space,” said Bresnik, Artemis III commander.

Added Douglas, mission specialist: “My brain — it is going a mile a minute right now. But my heart, it is so warm. It is so full."

In May, NASA awarded hundreds of millions of dollars in contracts to four companies, including Blue Origin, to build landers, rovers and drones for a future moon base. Isaacman said the goal of the moon base is to lay the foundation for a Mars expedition.

Meta to bring $115 million AI data center training initiative to Houston

ai workforce

Meta and Associated Builders and Contractors have entered into a partnership to invest $115 million in training programs for the construction of AI data centers, with a portion of the project launching in Houston.

The companies announced June 8 that they would open America’s Workforce Academies at ABC chapter training centers in Houston; Indianapolis; Baton Rouge, Louisiana; and Columbus, Ohio.

The academies will offer career readiness and safety training, plus five weeks of hands-on education. Participants who complete the program will be granted a job offer from contractors working on Meta projects.

“The AI revolution is bringing change but also historic opportunities,” Dina Powell McCormick, Meta president and vice-chairman, said in a news release. “Skilled workers electrified rural America one pole at a time. They manned the factories that built the arsenal that won World War II. Now a new generation will pour the foundations and lay the fiber that secures American strength in this new age.”

Overall, the Meta and ABC aim for the academies to build a more sustainable pipeline of skilled construction workers and ensure safety and job readiness for the surging number of data center projects underway.

“This new program is an innovative talent solution that is a critical part of addressing the construction industry’s ongoing workforce shortage and creates an accelerated, new-entrant strategy for job seekers ... The sustained demand for data center construction technicians means the industry needs an all-of-the-above approach to address this shortage and grow the construction talent pool,” Michael Bellaman, ABC president and CEO, added in the release.

In Texas, Meta, the parent company of Facebook and Instagram, has launched or broken ground on data centers in El Paso, Fort Worth and Temple. The company announced in March that it planned to grow its El Paso Data center by 1 gigawatt, representing more than a $10 billion investment.

Apart from Meta, Texas has attracted data center development to power other giants like Google and Amazon in recent years. In turn, Texas has been predicted to become the biggest data center market. Commercial real estate services provider JLL reported this spring that the state could topple Northern Virginia as the world’s largest data-center market by 2030. Similarly, CBRE predicted that Houston's data center capacity could double by 2028. Read more here.

New Houston biotech co. lands $30M for pulmonary fibrosis drug

drug money

Most of us can claim a scar or two on our bodies. But when scarring develops inside the body, it’s known as a fibrotic disorder. A freshly launched Houston company, Oorja Bio Inc., is working on a treatment that can help to repair cells and reduce the damage wrought by the growth of fibrotic tissue in patients.

Late last month, Oorja Bio hit the scene with a pair of big announcements. Not only has the company raised a $30 million Series A thanks to founding investor California-based Westlake BioPartners, but it has also already paved the way for a Phase 2 study to take place this year.

Oorja Bio received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA), allowing the company to test its treatment in patients with idiopathic pulmonary fibrosis (IPF), a scarring of the lung tissue. IPF affects more than 150,000 adults in the United States and can result in a range of symptoms from shortness of breath to organ failure and death as it progresses.

Oorja Bio’s lead drug candidate, ORJ-001, was shown in a Phase 1 in-human trial to demonstrate “therapeutically relevant exposure and favorable tolerability” in 64 healthy adult volunteers in whom it was administered daily or weekly, according to a news release. Pre-clinical studies of ORJ-001 showed durable target tissue engagement and biomarker activity in bleomycin-induced lung fibrosis.

Administered subcutaneously, ORJ-001 is intended to improve and even restore function in cells that can reduce the signaling that causes IPF. It stops advancement of IPF and also allows for tissue repair. Currently available treatments for the disease can slow the development of IPF down, but do not address the declining lung function that’s inherent in its progression.

“The clinical and preclinical results from our studies to date give us confidence that ORJ-001 represents a novel treatment approach with the potential to repair and reverse fibrosis and modify disease progression in IPF,” Dr. Janethe Pena, CMO of Oorja Bio, said in the release.

“Our team is energized to deliver on our goal of redefining the future of fibrotic diseases, beginning with ORJ-001,” CEO and founder Sujay Kango added. “As we advance ORJ-001 in the clinic, we are embracing the paradigm shift in our biological understanding of IPF pathology that aligns with the central role of the alveolar epithelium. ORJ-001 was designed with this biology in mind and may provide, for the first time, a therapeutic intervention that repairs and reverses fibrosis and promotes disease modification.”

Most patients live only three to five years following their IPF diagnosis. Soon, ORJ-001 and Oorja Bio could give them a fighting chance.